Navigation Links
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM)

Phase II GBM study presented at ASCO with cediranib - a selective VEGF signaling inhibitor - shows over a quarter of patients alive and progression- free at six months(1)

CHICAGO, June 04, 2007 /PRNewswire/ -- Data for the investigational agent cediranib (AZD2171) were presented today at the annual meeting of the American Society of Clinical Oncology (ASCO) from a study in patients with recurrent glioblastoma (GBM), an invasive form of brain tumor with a high unmet medical need. (1)

Cediranib Phase II monotherapy study in recurrent glioblastoma (GBM) Results from the National Cancer Institute (NCI) sponsored study at the Massachusetts General Hospital (MGH) Cancer Center, showed 8 patients (27.6%) of the 31 patients with recurrent glioblastoma treated with cediranib, were alive and progression-free at six months.(1) Recurrent glioblastoma is the most aggressive form of primary brain tumor. The dose limiting toxicities most commonly observed in this study included hypertension, fatigue, and diarrhea.

Cediranib is a selective VEGF signaling inhibitor that targets all three VEGF receptors.(2) VEGF signalling is a key driver of angiogenesis -- the formation of new blood vessels that tumors need to grow and spread. Cediranib is currently in Phase II/III development for advanced non-small cell lung cancer (NSCLC) and advanced colorectal cancer (CRC) -- as well as being investigated as part of a wide-ranging signal search program in other tumors such as glioblastoma.

Commenting on these results, Dr. Tracy Batchelor, MD, chief of Neuro- Oncology in the Massachusetts General Hospital (MGH) Cancer Center, Associate Professor of Neurology at Harvard Medical School and lead author of the Phase II study said, "These encouraging data showing effects on progression-free survival warrant further investigation to validate these initial trial results."

"In addition, cediranib alleviated brain swelling
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia

Post Your Comments:
(Date:11/20/2009)... , NEW YORK, Nov. 20 ,, Re...h report is available in its catalogue. ,, Glo... http://www.reportlinker.com/p0164741/Global-Mark...=prnewswire&utm_medium=pr&utm_campaign=prn...sy devices includes the spring loaded core needle ...
(Date:11/20/2009)..., NATICK, Mass. and LONDON, Nov. 20 /PRNewswire...: BSX ) today announced that it has received 510...ration (FDA) and CE Mark approval to market its Wa...e treatment of malignant esophageal strictures (ob...ctable or non-resectable esophageal cancer. ,,...
(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-U...mes article that questions why currently availabl...ancers are being ignored, ECRI Institute, an indep...ap to the evidence on Finasteride for Prevention ... November 13, 2009, New York Times article, " Dr...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Heartburn Drugs May Contribute to the Problem 50969 1Heartburn Drugs May Contribute to the Problem 50969 2Heartburn Drugs May Contribute to the Problem 50969 3Pharmacyclics Sets Record Date for Rights Offering 50966 1Pharmacyclics Sets Record Date for Rights Offering 50966 2Pharmacyclics Sets Record Date for Rights Offering 50966 3CareFusion Corporation Launches International Jazz Festival Series 50963 1CareFusion Corporation Launches International Jazz Festival Series 50963 2CareFusion Corporation Launches International Jazz Festival Series 50963 3CareFusion Corporation Launches International Jazz Festival Series 50963 4CareFusion Corporation Launches International Jazz Festival Series 50963 5
... (OTCBB: ORMP) ( http://www.oramed.com ), a develo... it will hold a conference call on August 6,2008 a... 2A clinical trials,of its flagship product, ORMD ... trial is focused on assessing the safety and effi... the successfully completed,Phase 1 studies in Isr...
...(OTC Bulletin Board: ANPG), reported today that it...I) announced that its EnviroTru(R),disinfectant ha...tment of,Management Services (DMS) in the State of...r, A World of Green, LLC(TM) ( http://www.aworldo...u(R) assigned under the code which now,permits Sta...
Other Medicine Technology:Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 3
(Date:11/20/2009)...ON, NJ, Nov. 20 /PRNewswire-FirstCall/ - NUCRYST P...l Meeting of Shareholders will be held on Monday, ...o consider approval of two special resolutions. Th...rize the sale of all or substantially all of the a...ded for in the asset purchase agreement dated Nove...
(Date:11/20/2009)...HINGTON, Nov. 20 The Un...he Senate to make essential changes its health ref...abortion funding and conscience protection on abor... and include strong provisions for adequate afford...h care bill an "enormous disappointment" that crea...
(Date:11/20/2009)... Senators and Congressmen in Competitive Re-...alth Care Vote , Washingt...ongressmen running for re-election next year in ra...rlie Cook, may come to regret voting for House Spe...ing to a breaking Zogby International/ O’Lea...
(Date:11/20/2009)... Nov. 20 The American D...and Drug Administration (FDA) to establish appropr.... ,, Citing concern about the safety of whiten...he benefit of professional consultation or examina...pplication of chemically based tooth whitening or ...
(Date:11/20/2009)...AIFA, Israel, November 20 /PRNewswire-FirstCall/ -... http://www.CVSLMEDICAL.COM , a leading,developer ...ay announced that,the company,s Board of Directors...rope, Canada and the Far East for its proprietary ...or all angioplasty (PCTA) procedures. , C...
Breaking Medicine News(10 mins):Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2
... new weapon is being investigated.// Scientist...edient -oligo fructose, on obese human subjects. ...the natural fiber seen in baby foods, cereals and ...ke peptide that was responsible for a feeling of s...
...munication between clinicians in the Intensive Car... significantly reduces feelings of stress,// anxie...g to a study that appears in the February 1, 2007 ...National Institutes of Health (NIH), showed that t...
...vels during women’s menstrual cycles affect the re... imaging study at the National Institute of// Ment...itutes of Health (NIH), has revealed. While w...o a phase when estrogen and progesterone are prese...
...to grant product patent for Glivec, the cancer dru...esult Novartis may not be able to conduct// their ...re the countries where Novartis conducts its resea... government could hamper the launch of their paten...
...re has been a marked increase in allergic reaction...ed eight times during a 30 year period.// Teenager...sporting different hair colors, in keeping with a ...esearchers are pressing for a wider debate about t...
...of Michigan Medical Center have, for the first tim.../ Their work indicates that these cells are likely...ression, and metastasis that define this deadly ca...atic cancer in half of mice tested. They also foun...
Other Medicine News:Health News:Communication in the ICU to Be Strengthened 2Health News:Communication in the ICU to Be Strengthened 3Health News:NIMH Studies Woman’s Hormonal Cycl 2Health News:Scientists Identify Pancreatic Cancer Stem Cells 2Health News:Scientists Identify Pancreatic Cancer Stem Cells 3
Bandeau Bra
Medical Cotton Bra
Compression Bra
Universal Breast Augmentation Support
Medicine Products: